Prothena CorpPRTA
Market Cap: $1.16B
About: Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Employees: 173
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
36% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 42
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
5% less funds holding
Funds holding: 166 [Q1] → 158 (-8) [Q2]
6.19% less ownership
Funds ownership: 100.66% [Q1] → 94.47% (-6.19%) [Q2]
12% less call options, than puts
Call options by funds: $2.03M | Put options by funds: $2.31M
22% less capital invested
Capital invested by funds: $1.34B [Q1] → $1.05B (-$292M) [Q2]
23% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 35
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Oppenheimer Jay Olson 35% 1-year accuracy 17 / 49 met price target | 187%upside $62 | Outperform Maintained | 14 Aug 2024 |
RBC Capital Brian Abrahams 51% 1-year accuracy 39 / 76 met price target | 11%upside $24 | Sector Perform Maintained | 9 Aug 2024 |
RBC Capital Brian Abrahams 51% 1-year accuracy 39 / 76 met price target | 30%upside $28 | Sector Perform Reiterated | 26 Jun 2024 |